- Home
- TMQ vs RIGL Comparison
TMQ vs RIGL Comparison
Compare TMQ & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | RIGL |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.7M | 564.7M |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TMQ | RIGL |
|---|---|---|
| Price | $3.31 | $36.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | ★ 2.3M | 329.4K |
| Earning Date | 04-02-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $83.07 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $1.30 | $18.24 |
| 52 Week High | $11.29 | $52.24 |
Technical Indicators
Market Signals| Indicator | TMQ | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 32.91 | 73.94 |
| Support Level | $2.00 | $33.39 |
| Resistance Level | $4.98 | $36.95 |
| Average True Range (ATR) | 0.25 | 1.42 |
| MACD | -0.07 | 0.53 |
| Stochastic Oscillator | 1.08 | 94.59 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.